相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rational Drug Design Approach of Receptor Tyrosine Kinase Type III Inhibitors
Cheolhee Kim et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus
Jianghong Deng et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Anti-CD22 epratuzumab for systemic lupus erythematosus: A systematic review and meta-analysis of randomized controlled trials
Jian Li et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2019)
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
Renaud Felten et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
IFNγ induces epigenetic programming of human T-bethi B cells and promotes TLR7/8 and IL-21 induced differentiation
Esther Zumaquero et al.
ELIFE (2019)
Cryptotanshinone ameliorates the pathogenesis of systemic lupus erythematosus by blocking T cell proliferation
Yu Du et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
Bruno Fautrel et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus
I-Tsu Chyuan et al.
CELLS (2019)
TNF-α promoter polymorphisms (G-238A and G-308A) are associated with susceptibility to Systemic Lupus Erythematosus (SLE) and P. falciparum malaria: a study in malaria endemic area
Harishankar Mahto et al.
SCIENTIFIC REPORTS (2019)
Cyclin-Dependent Kinase 2 in Cellular Senescence and Cancer. A Structural and Functional Review
Priscylla Andrade Volkart et al.
CURRENT DRUG TARGETS (2019)
B cell alterations during BAFF inhibition with belimumab in SLE
Daniel Ramskold et al.
EBIOMEDICINE (2019)
Overview on Anticancer Drug Design and Development
Sureyya Olgen
CURRENT MEDICINAL CHEMISTRY (2018)
Epratuzumab for the treatment of systemic lupus erythematosus
Daniel Geh et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study
Joan T. Merrill et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Mesenchymal Stem Cells Control Complement C5 Activation by Factor H in Lupus Nephritis
Haijun Ma et al.
EBIOMEDICINE (2018)
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Ustekinumab: a promising new drug for SLE?
Nathalie Costedoat-Chalumeau et al.
LANCET (2018)
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Ronald F. van Vollenhoven et al.
LANCET (2018)
An autoimmune disease variant of IgG1 modulates B cell activation and differentiation
Xiangjun Chen et al.
SCIENCE (2018)
A Case of Severe Transaminase Elevation Following a Single Ustekinumab Dose with Remission After Drug Withdrawal
Rosa Lovero et al.
CURRENT DRUG SAFETY (2018)
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
Jeffrey M. Riggs et al.
LUPUS SCIENCE & MEDICINE (2018)
Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
Megan E. B. Clowse et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Targeting Multiple Cyclin-Dependent Kinases (CDKs): A New Strategy for Molecular Docking Studies
Walter Filgueira de Azevedo
CURRENT DRUG TARGETS (2016)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF-α, but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients
Vanessa Fleischer et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center
C. Lourdudoss et al.
LUPUS (2014)
Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus The Michigan Lupus Epidemiology and Surveillance Program
Emily C. Somers et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Sifalimumab, a Human AntiInterferon- Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study
Michelle Petri et al.
ARTHRITIS AND RHEUMATISM (2013)
Belimumab: A BLyS-Specific Inhibitor for the Treatment of Systemic Lupus Erythematosus
G. J. Dennis
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
Ellen M. Ginzler et al.
ARTHRITIS RESEARCH & THERAPY (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Molecular Dynamics Simulations of Protein Targets Identified in Mycobacterium tuberculosis
W. F. de Azevedo
CURRENT MEDICINAL CHEMISTRY (2011)
The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
J. T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
The influence of antimalarial treatment on IL-1β, IL-6 and TNF-α mRNA expression on UVB-irradiated skin in systemic lupus erythematosus
A. Wozniacka et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Protein kinases as targets for antiparasitic chemotherapy drugs
Fernanda Canduri et al.
CURRENT DRUG TARGETS (2007)
Dihydroarteannuin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappa B translocation
Wei-Dong Li et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2006)
Structure of human PNP complexed with ligands
F Canduri et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2005)
New catalytic mechanism for human purine nucleoside phosphorylase
F Canduri et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Molecular model of shikimate kinase from Mycobacterium tuberculosis
WF de Azevedo et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
An etiopathogenic role for the type IIFN system in SLE
L Rönnblom et al.
TRENDS IN IMMUNOLOGY (2001)
分享论文
